Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts

Blood

Volumn 119, Issue 24, 2012, Pages 5674-5677

  Patnaik, Mrinal M ^a   Hanson, Curtis A ^a   Sulai, Nanna H ^a   Hodnefield, Janice M ^a   Knudson, Ryan A ^a   Ketterling, Rhett P ^a   Lasho, Terra L ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PROTEIN; SF3B1 PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLAST CELL; BONE MARROW CELL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARYOTYPE; LEUKEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MEAN CORPUSCULAR VOLUME; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RING SIDEROBLAST; RISK ASSESSMENT; THROMBOCYTE COUNT; TRANSFUSION;

EID: 84862497037     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-415356     Document Type: Article

References (24)

1. Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93(11):1712-1717.
2. Cazzola M, Invernizzi R. Ring sideroblasts and sideroblastic anemias. Haematologica. 2011;96(6):789-792.
3. Lasho TL, Finke CM, Hanson CA, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia. 2012;26(5):1135-1137.
4. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114(17):3538-3545.
5. Cotter PD, Baumann M, Bishop DF. Enzymatic defect in "X-linked" sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinate synthase deficiency. Proc Natl Acad Sci U S A. 1992;89(9):4028-4032.
6. Guernsey DL, Jiang H, Campagna DR, et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet. 2009;41(6):651-653.
7. Rouault TA, Tong WH. Iron-sulfur cluster biogenesis and human disease. Trends Genet. 2008;24(8):398-407.
8. Allikmets R, Raskind WH, Hutchinson A, Schueck ND, Dean M, Koeller DM. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet. 1999;8(5):743-749. (Pubitemid 29189041)
9. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384-1395.
10. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012;119(2):569-572.
11. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2011;26(3):542-545.
12. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
13. Boultwood J, Pellagatti A, Nikpour M, et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One. 2008;3(4):e1970.
14. Pellagatti A, Cazzola M, Giagounidis AA, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon- stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006;108(1):337-345. (Pubitemid 43990647)
15. Greenberg P, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) developed by the International Working Group for Prognosis in MDS (IWG-PM). Leuk Res. 2011;35:S6.
16. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476.
17. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24(7):1302-1309.
18. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared with either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22(4):756-761. (Pubitemid 351559282)
19. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
20. Patnaik MM, Hanson CA, Hodnefield JM, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia. 2012;26(1):101-105.
21. Bejar R, Ebert BL. The genetic basis of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):295-315.
22. Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011;29(5):504-515.
23. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153-1158.
24. Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012;119(14):3211-3218.